vs

Side-by-side financial comparison of BGSF, INC. (BGSF) and NEKTAR THERAPEUTICS (NKTR). Click either name above to swap in a different company.

BGSF, INC. is the larger business by last-quarter revenue ($22.0M vs $21.8M, roughly 1.0× NEKTAR THERAPEUTICS). BGSF, INC. runs the higher net margin — -5.3% vs -165.4%, a 160.2% gap on every dollar of revenue. On growth, BGSF, INC. posted the faster year-over-year revenue change (-9.4% vs -25.3%). BGSF, INC. produced more free cash flow last quarter ($1.7M vs $-65.0M). Over the past eight quarters, NEKTAR THERAPEUTICS's revenue compounded faster (0.4% CAGR vs -5.3%).

BGSF Inc. is a leading U.S.-headquartered workforce solutions firm that provides tailored staffing, talent recruitment, and end-to-end workforce management services. It serves core segments including information technology, healthcare, professional administration, light industrial, and creative industries, catering to small, mid-sized and large enterprise clients across North America.

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...

BGSF vs NKTR — Head-to-Head

Bigger by revenue
BGSF
BGSF
1.0× larger
BGSF
$22.0M
$21.8M
NKTR
Growing faster (revenue YoY)
BGSF
BGSF
+15.9% gap
BGSF
-9.4%
-25.3%
NKTR
Higher net margin
BGSF
BGSF
160.2% more per $
BGSF
-5.3%
-165.4%
NKTR
More free cash flow
BGSF
BGSF
$66.6M more FCF
BGSF
$1.7M
$-65.0M
NKTR
Faster 2-yr revenue CAGR
NKTR
NKTR
Annualised
NKTR
0.4%
-5.3%
BGSF

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BGSF
BGSF
NKTR
NKTR
Revenue
$22.0M
$21.8M
Net Profit
$-1.2M
$-36.1M
Gross Margin
35.0%
Operating Margin
-17.6%
-126.9%
Net Margin
-5.3%
-165.4%
Revenue YoY
-9.4%
-25.3%
Net Profit YoY
-18.2%
-596.9%
EPS (diluted)
$-0.12
$-4.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BGSF
BGSF
NKTR
NKTR
Q4 25
$22.0M
$21.8M
Q3 25
$26.9M
$11.8M
Q2 25
$23.5M
$11.2M
Q1 25
$20.9M
$10.5M
Q4 24
$24.3M
$29.2M
Q3 24
$29.8M
$24.1M
Q2 24
$25.7M
$23.5M
Q1 24
$24.5M
$21.6M
Net Profit
BGSF
BGSF
NKTR
NKTR
Q4 25
$-1.2M
$-36.1M
Q3 25
$-5.8M
$-35.5M
Q2 25
$-3.7M
$-41.6M
Q1 25
$-722.0K
$-50.9M
Q4 24
$-981.0K
$7.3M
Q3 24
$-804.0K
$-37.1M
Q2 24
$-761.0K
$-52.4M
Q1 24
$-792.0K
$-36.8M
Gross Margin
BGSF
BGSF
NKTR
NKTR
Q4 25
35.0%
Q3 25
35.9%
Q2 25
35.8%
Q1 25
36.2%
Q4 24
35.9%
72.7%
Q3 24
35.9%
81.6%
Q2 24
37.3%
58.5%
Q1 24
38.1%
60.6%
Operating Margin
BGSF
BGSF
NKTR
NKTR
Q4 25
-17.6%
-126.9%
Q3 25
-3.5%
-268.6%
Q2 25
-18.8%
-324.2%
Q1 25
1.6%
-425.8%
Q4 24
-15.7%
49.2%
Q3 24
-3.4%
-142.4%
Q2 24
-5.7%
-211.9%
Q1 24
1.7%
-163.7%
Net Margin
BGSF
BGSF
NKTR
NKTR
Q4 25
-5.3%
-165.4%
Q3 25
-21.6%
-301.3%
Q2 25
-15.9%
-372.2%
Q1 25
-3.5%
-486.4%
Q4 24
-4.0%
24.9%
Q3 24
-2.7%
-153.6%
Q2 24
-3.0%
-222.9%
Q1 24
-3.2%
-170.1%
EPS (diluted)
BGSF
BGSF
NKTR
NKTR
Q4 25
$-0.12
$-4.67
Q3 25
$-0.52
$-1.87
Q2 25
$-0.34
$-2.95
Q1 25
$-0.06
$-0.24
Q4 24
$-2.07
Q3 24
$-0.07
$-2.66
Q2 24
$-0.07
$-3.76
Q1 24
$-0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BGSF
BGSF
NKTR
NKTR
Cash + ST InvestmentsLiquidity on hand
$15.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$48.1M
$89.8M
Total Assets
$57.8M
$280.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BGSF
BGSF
NKTR
NKTR
Q4 25
$15.1M
Q3 25
$41.2M
$41.0M
Q2 25
$2.8M
$43.0M
Q1 25
$2.0M
$38.9M
Q4 24
$32.0K
$44.3M
Q3 24
$262
$30.1M
Q2 24
$226
$27.9M
Q1 24
$50
$48.6M
Stockholders' Equity
BGSF
BGSF
NKTR
NKTR
Q4 25
$48.1M
$89.8M
Q3 25
$50.7M
$85.1M
Q2 25
$78.3M
$-24.2M
Q1 25
$81.8M
$13.7M
Q4 24
$82.3M
$60.7M
Q3 24
$82.9M
$48.9M
Q2 24
$83.2M
$79.7M
Q1 24
$83.6M
$126.7M
Total Assets
BGSF
BGSF
NKTR
NKTR
Q4 25
$57.8M
$280.4M
Q3 25
$83.6M
$301.3M
Q2 25
$149.7M
$207.5M
Q1 25
$152.3M
$256.2M
Q4 24
$150.1M
$303.9M
Q3 24
$157.3K
$308.0M
Q2 24
$159.8K
$343.3M
Q1 24
$170.6K
$396.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BGSF
BGSF
NKTR
NKTR
Operating Cash FlowLast quarter
$1.7M
$-65.0M
Free Cash FlowOCF − Capex
$1.7M
$-65.0M
FCF MarginFCF / Revenue
7.6%
-298.0%
Capex IntensityCapex / Revenue
0.1%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-16.0K
$-208.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BGSF
BGSF
NKTR
NKTR
Q4 25
$1.7M
$-65.0M
Q3 25
$-4.8M
$-48.8M
Q2 25
$2.2M
$-45.7M
Q1 25
$1.1M
$-49.1M
Q4 24
$3.2M
$-46.2M
Q3 24
$6.5M
$-43.9M
Q2 24
$7.3M
$-37.7M
Q1 24
$7.4M
$-47.9M
Free Cash Flow
BGSF
BGSF
NKTR
NKTR
Q4 25
$1.7M
$-65.0M
Q3 25
$-4.9M
$-48.9M
Q2 25
$2.1M
$-45.8M
Q1 25
$1.0M
$-49.1M
Q4 24
$2.5M
$-46.6M
Q3 24
$6.5M
$-44.6M
Q2 24
$7.3M
$-37.9M
Q1 24
$6.9M
$-48.0M
FCF Margin
BGSF
BGSF
NKTR
NKTR
Q4 25
7.6%
-298.0%
Q3 25
-18.1%
-414.5%
Q2 25
9.1%
-409.6%
Q1 25
5.0%
-469.0%
Q4 24
10.2%
-159.9%
Q3 24
21.7%
-184.9%
Q2 24
28.5%
-161.3%
Q1 24
28.1%
-222.0%
Capex Intensity
BGSF
BGSF
NKTR
NKTR
Q4 25
0.1%
0.1%
Q3 25
0.4%
1.0%
Q2 25
0.0%
0.3%
Q1 25
0.1%
0.0%
Q4 24
3.0%
1.6%
Q3 24
0.0%
2.8%
Q2 24
0.0%
0.8%
Q1 24
2.0%
0.7%
Cash Conversion
BGSF
BGSF
NKTR
NKTR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-6.36×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BGSF
BGSF

Contract Field Talent$21.4M97%
Other$595.0K3%

NKTR
NKTR

Segment breakdown not available.

Related Comparisons